© 2022 BioMarin. All rights reserved.
| Beta | 0.49 |
|---|---|
| Shares Outstanding | 183.6M |
| Average Volume (10 days) | 1.7M |
| Qtrly Dividend (Ann. Yield) | -- (--) |
| Earnings (TTM) | $0.10 |
|---|---|
| Sales (TTM) | $7.61 |
| Book Value (MRQ) | $23.24 |
| Cash Flow (TTM) | $1.53 |
| Cash (MRQ) | $5.89 |
| Current Mean Recommendation | Strong Buy |
|---|
| Strong Buy | 12 | |
|---|---|---|
| Buy | 0 | |
| Hold | 3 | |
| Underperform | 0 | |
| Sell | 0 |
V. Bryan Lawlis Director | (4,250) Sell Jan 14, 2022 |
|---|---|
Mark J. Alles Director | 2,300 Acquire Jan 3, 2022 |
Jean-Jacques Bienaime Director, Chief Executive Officer | (1,500) Sell Dec 1, 2021 |
Jeffrey R. Ajer EVP, Chief Commercial Officer | (2,739) Sell Oct 26, 2021 |
G. Eric Davis EVP, General Counsel | (5,518) Sell Aug 2, 2021 |